- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03095066
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
September 26, 2023 updated by: Otsuka Pharmaceutical Development & Commercialization, Inc.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury (TBI).
This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury (TBI).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Eligible participants for this study must have a diagnosis of neurobehavioral disinhibition including aggression, agitation, and irritability that persists after brain injury.
This is a multicenter, randomized, placebo-controlled study, consisting of up to 12 weeks of treatment.
Study Type
Interventional
Enrollment (Actual)
168
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Tuscaloosa, Alabama, United States, 35404
- Tuscaloosa Veterans Affairs Medical Center
-
-
Arizona
-
Phoenix, Arizona, United States, 85051
- Absolute Clinical Research Site#207
-
Scottsdale, Arizona, United States, 85254
- Perseverance Research Center Site#152
-
-
California
-
Costa Mesa, California, United States, 92626
- ATP Clinical Research Site#150
-
La Jolla, California, United States, 92037
- Kaizen Brain Center #224
-
Lafayette, California, United States, 94543
- Sunwise Clinical Research, LLC Site#216
-
Lomita, California, United States, 90717
- Torrance Clinical Research Institute Site#157
-
Long Beach, California, United States, 90822
- Tibor Rubin VA Medical Center, SCIRE Biomedical Research Institute
-
Panorama City, California, United States, 91402
- Asclepes Research Centers - Panorama City Site #208
-
Pomona, California, United States, 91767
- The Neurology Group
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80903
- Mountain Mind
-
Denver, Colorado, United States, 80209
- Mountain View Clinical Research, Inc. Site# 202
-
Loveland, Colorado, United States, 80538
- Medical Center of the Rockies
-
-
Connecticut
-
Cromwell, Connecticut, United States, 06416
- Connecticut Clinical Research
-
-
Florida
-
Bradenton, Florida, United States, 34205
- Bradenton Research Center, Inc
-
Coral Springs, Florida, United States, 33067
- Healthcare Innovative Institute, LLC Site# 173
-
Doral, Florida, United States, 33166
- Science Connections, LLC Site#161
-
Doral, Florida, United States, 33172
- Design Neuroscience Center, PL
-
Jupiter, Florida, United States, 33458
- Alphab Global Research Site#163
-
Maitland, Florida, United States, 32751
- Meridien Research
-
Miami, Florida, United States, 33122
- Premier Clinical Research Institute, Inc.
-
Miami, Florida, United States, 33125
- Project 4 Research
-
Miami, Florida, United States, 33155
- Allied Biomedical Research Institute, Inc. Site#151
-
Okeechobee, Florida, United States, 34972
- Health Synergy Clinical Research
-
Sarasota, Florida, United States, 34243
- Roskamp Institute Clinic, Inc.
-
Tampa, Florida, United States, 33613
- USF Dept of Psychiatry and Behavioral Neurosciences Site# 214
-
Tampa, Florida, United States, 33634
- Meridien Research Site# 108
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96817
- Hawaii Pacific Neuroscience Site#184
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- The University of Kentucky research foundation
-
Richmond, Kentucky, United States, 40475
- Baptist Health
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01103
- Sisu BHR Site#200
-
-
Michigan
-
Bloomfield Hills, Michigan, United States, 48302
- Neurobehavioral Medicine Group #222
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- Millennium Psychiatric Associates, LLC
-
Ozark, Missouri, United States, 65721
- Sharlin Health and Neurology
-
Saint Louis, Missouri, United States, 63141
- Clinical Research Professionals
-
-
New Jersey
-
Edison, New Jersey, United States, 08820
- JFK Johnson Rehabilitation Institute
-
Mount Arlington, New Jersey, United States, 07856
- The NeuroCognitive Insititute
-
-
New York
-
New York, New York, United States, 10016
- New York University School of Medicine Site #122
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Atrium Health - Carolinas Rehabilitation - Charlotte Site #166
-
Charlotte, North Carolina, United States, 28211
- New Hope Clinical Research Site#194
-
Durham, North Carolina, United States, 27713
- Carolina Headache Institute
-
Salisbury, North Carolina, United States, 28144
- Salisbury VAMC
-
-
Ohio
-
Centerville, Ohio, United States, 45459
- Valley Medical Research
-
Cincinnati, Ohio, United States, 45220
- Cincinnati VA Medical Center
-
Middleburg Heights, Ohio, United States, 44130
- North Star Medical Research, LLC Site#154
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73106
- IPS Research Site#196
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
South Carolina
-
Columbia, South Carolina, United States, 29205
- WJB Dorn VA-Wm. Jennings Bryan Dorn VA Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Site#140
-
San Antonio, Texas, United States, 78229
- Polytrauma Rehabilitation Center S. Texas VA Health Care System Site# 146
-
-
Utah
-
Draper, Utah, United States, 84020
- Cedar Clinical Research #221
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University #172
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University Site#172
-
Salem, Virginia, United States, 24153
- Salem Research Institute Site# 138
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants with TBI
- Participants with neurobehavioral disinhibition symptoms that are present after trauma or after recovery of consciousness
- Score of ≥4 on the mCGI-S scale and the Agitation/Aggression or Irritability/Lability subscales of the Neuropsychiatric Inventory (NPI) scale at screening and baseline
- Participants with a reliable caregiver
Exclusion Criteria:
- Participants with significant symptoms of a major depressive disorder
- Participants with a history of or current clinical symptoms of schizophrenia, schizoaffective disorder, bipolar disorder, antisocial personality disorder, or borderline personality disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Stage 1: Placebo
Participants will receive AVP-786 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 6 of the Stage 1 treatment period.
|
Administered as capsules
|
Experimental: AVP-786
Participants will receive AVP-786-28/4.9 (deudextromethorpan hydrobromide [d6-DM] 28 milligrams (mg)/quinidine sulfate [Q] 4.9 mg) capsule, along with AVP-786 matching placebo capsule, orally, once daily (QD) during Week 1 followed by AVP-786-28/4.9
capsule, orally, BID during Week 2, and AVP-786-42.63/4.9
(d6-DM 42.63 mg/Q 4.9 mg) capsules (target dose), orally, BID during Weeks 3 to 12 of the treatment period.
|
28 mg of d6-DM and 4.9 mg of Q
42.63 mg of d6-DM and 4.9 mg of Q
|
Placebo Comparator: Stage 1: Placebo Non-responders to Stage 2: Placebo
Participants who will be randomized to receive placebo in Stage 1 and will be classified as non-responders (responders" if modified Clinical Global Impression of Severity [mCGI-S] score is ≤ 3 at Day 43 and Neuropsychiatric Inventory Clinician (NPI-C)-3 score has decreased by ≥ 25% from baseline.
Participants who will not meet these criteria will be considered "non-responders) after Week 6 will be re-randomized to continue receiving AVP-786 matching placebo capsules, orally, BID during Weeks 7 to 12 of the Stage 2 treatment period.
|
Administered as capsules
|
Experimental: Stage 1: Placebo Non-responders to Stage 2: AVP-786
Participants who will be randomized randomized to receive placebo in Stage 1 and will be classified as non-responders (responders" if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline.
Participants who will not meet these criteria will be considered "non-responders) after Week 6 will be re-randomized to receive AVP-786 in Stage 2 using the same dose escalation schedule used in Stage 1 i.e., AVP-786-28/4.9
capsule, along with AVP-786 matching placebo capsule, orally, QD during Week 7 followed by AVP-786-28/4.9
capsule, orally, BID during Week 8, and AVP-786-42.63/4.9
capsules, orally, BID, during Weeks 9 to 12 of the Stage 2 treatment period.
|
28 mg of d6-DM and 4.9 mg of Q
42.63 mg of d6-DM and 4.9 mg of Q
Administered as capsules
|
Placebo Comparator: Stage 1: Placebo Responders to Stage 2: Placebo
Participants who will be randomized to receive placebo in Stage 1 and will be classified as responders (responders" if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline) after Week 6 will be re-randomized to continue receiving AVP-786 matching placebo capsules, orally, BID during Weeks 7 to 12 of the Stage 2 treatment period.
|
Administered as capsules
|
Experimental: Stage 1: Placebo Responders to Stage 2: AVP-786
Participants who will be randomized to receive placebo in Stage 1 and will be classified as responders (responders" if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline) after Week 6 will be re-randomized to receive AVP-786 in Stage 2 using the same dose escalation schedule used in Stage 1 i.e., AVP-786-28/4.9
capsule, along with AVP-786 matching placebo capsule, orally, QD during Week 7 followed by AVP-786-28/4.9
capsule, orally, BID during Week 8, and AVP-786-42.63/4.9
capsules, orally, BID, during Weeks 9 to 12 of the Stage 2 treatment period.
|
28 mg of d6-DM and 4.9 mg of Q
42.63 mg of d6-DM and 4.9 mg of Q
Administered as capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline to Week 12 in the Composite of the Clinical Impression Severity Scores on the Neuropsychiatric Inventory Clinician Rating Scale (NPI-C) Subscales of Aggression, Agitation, and Irritability/Lability (NPI-C-3)
Time Frame: Baseline; Week 12
|
The NPI-C can be used to rate the presence of neuropsychiatric symptoms across 14 domains.
The scores for each item within an individual domain/subscale range from 0 to 3, with a higher score indicating increased severity.
The NPI-C-3 is comprised of the aggression, agitation, and irritability/lability subscales.
The scores for the three subscales are summed to create the total NPI-C-3 composite score, which ranges from 0 to 99, with a higher score indicating increased severity.
|
Baseline; Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline to Week 12 in Modified Clinical Global Impression of Change (mCGI-C) Raw Scores
Time Frame: Baseline; Week 12
|
The mCGI-C will be used to assess the clinician's general impression of the participant's treatment response.
The mCGI-C is a 7-point (1 to 7) modified version of the CGI-C scale.
A higher score represents worsening of symptoms.
|
Baseline; Week 12
|
Change from Baseline to Week 12 in NPI-C Rating Scale Subscales Scores for Aggression, Agitation, Irritability/Lability, and Disinhibition
Time Frame: Baseline; Week 12
|
The NPI-C is used to rate the presence of neuropsychiatric symptoms across 14 domains.
The scores for each item within an individual domain/subscale range from 0 to 3, with a higher score indicating increased severity.
|
Baseline; Week 12
|
Change from Baseline to Week 12 in Modified Clinical Global Impression of Severity (mCGI-S) Scale Scores
Time Frame: Baseline; Week 12
|
The mCGI-S will be used to assess the clinician's view of the participant's severity of aggression, agitation, and irritability symptoms.
The mCGI-S is a 7-point (1 to 7) modified version of the CGI-S scale.
In all cases, a higher score represents increased severity.
|
Baseline; Week 12
|
Change from Baseline to Week 12 in Patient Global Impression of Severity (PGI-S) Scores
Time Frame: Baseline; Week 12
|
The PGI-S is a single-question scale that specifically assesses the severity of symptoms of neurobehavioral disinhibition, including aggression, agitation, and irritability, on a 7-point scale : 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
|
Baseline; Week 12
|
Change from Baseline to Week 12 in Patient Global Impression of Change (PGI-C) Raw Scores
Time Frame: Baseline; Week 12
|
The PGI-C is a 7-point (1 to 7) scale used to assess the participant's assessment of treatment response.
A higher score indicates worsening of the symptoms.
|
Baseline; Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 30, 2017
Primary Completion (Actual)
August 22, 2022
Study Completion (Actual)
August 31, 2022
Study Registration Dates
First Submitted
March 23, 2017
First Submitted That Met QC Criteria
March 23, 2017
First Posted (Actual)
March 29, 2017
Study Record Updates
Last Update Posted (Actual)
September 29, 2023
Last Update Submitted That Met QC Criteria
September 26, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Wounds and Injuries
- Neurobehavioral Manifestations
- Dyskinesias
- Psychomotor Disorders
- Craniocerebral Trauma
- Trauma, Nervous System
- Aggression
- Psychomotor Agitation
- Brain Injuries
- Brain Injuries, Traumatic
Other Study ID Numbers
- 17-AVP-786-205
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Small studies with less than 25 participants are excluded from data sharing
IPD Sharing Time Frame
Data will be available after marketing approval in global markets or beginning 1-3 years following article publication.
There is no end date to the availability of the data.
IPD Sharing Access Criteria
Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurobehavioral Disinhibition
-
Avanir PharmaceuticalsTerminatedDisinhibition SyndromeUnited States
-
Virginia Polytechnic Institute and State UniversityRecruitingNeurobehavioral Components of Reward and Loss ValuationUnited States
-
National Institute of Mental Health (NIMH)RecruitingAutism | Neurologic Disorders | Neurodegenerative Disease | Neurobehavioral ManifestationUnited States
-
University of ConnecticutHarvard Medical School (HMS and HSDM); Boston University; Massachusetts General... and other collaboratorsCompletedChild Nutrition, Child Neurobehavioral DevelopmentKenya
-
National Institute of Mental Health (NIMH)CompletedHealthy | Mood Disorder | Neurobehavioral ManifestationUnited States
-
Columbia UniversityCompletedNeurologic Manifestations | Neurobehavioral ManifestationsUnited States
-
Jiangsu Province Nanjing Brain HospitalNot yet recruiting
-
University of New MexicoNational Institute of Mental Health (NIMH)Completed
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH); Duke UniversityCompletedAnhedoniaUnited States
Clinical Trials on AVP-786-28
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAgitation in Participants With Dementia of the Alzheimer's TypeUnited States, Canada
-
Avanir PharmaceuticalsCompleted
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedSchizophreniaUnited States, Bulgaria, Hungary, Poland, Puerto Rico
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedIntermittent Explosive DisorderUnited States
-
Avanir PharmaceuticalsCompleted
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAgitation in Patients With Dementia of the Alzheimer's TypeUnited States, Belgium, Canada, Chile, Colombia, Croatia, Hungary, Mexico, Netherlands, Slovakia, Slovenia, Spain, Ireland
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAgitation in Patients With Dementia of the Alzheimer's TypeUnited States, Bulgaria, Denmark, Estonia, Greece, Poland, Portugal, Puerto Rico, United Kingdom, Germany, Ukraine
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAgitation in Patients With Dementia of the Alzheimer's TypeSpain, United States, Italy, United Kingdom, Hungary, France, Poland, Australia, Bulgaria, Czechia, South Africa
-
Avanir PharmaceuticalsCompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAgitation in Patients With Dementia of the Alzheimer's TypeUnited States, Estonia, Germany, Poland, Portugal, Puerto Rico